Luspatercept

• CAT Number: I041581
• CAS Number: 1373715-00-4
• Purity: ≥95%

Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia[1].
Luspatercept (0.1-1000 ng/mL) inhibits Smad2 and Smad 3 signaling induced by GDF11 and GDF8 in A204 cells[1].
Luspatercept binds with GDF11, GDF8, activin B, BMP10 and BMP6[1].
Luspatercept (0.1-60 mg/kg, s.c.; 10 mg/kg, i.v.; twice weekly for 8 weeks) increases red blood cell (RBC) count, hemoglobin levels and hematocrit in mice, rats and monkeys[1].
Luspatercept (10 mg/kg; s.c., once) reduces erythroid burst forming units (BFU-Es) and erythroid colony-forming units (CFU-Es) from bone marrow and spleen of C57BL/6 mice[1].
Luspatercept (10 mg/kg; i.p., once) inhibits Smad2/3 phosphorylation in mouse spleen[1].

Reference

[1]. Suragani RN, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014 Apr;20(4):408-14.
 [Content Brief]